Focused Agreement is on Therapeutic Area of Mutual Interest NEW YORK --(BUSINESS WIRE)--Apr. 23, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of uro-oncology, today announced that it has entered into an
NEW YORK --(BUSINESS WIRE)--Apr. 5, 2019-- UroGen Pharma Ltd. (Nasdaq: URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in uro-oncology, today announced a new presentation from the pivotal Phase 3 OLYMPUS trial of UGN-101 (mitomycin gel) for
NEW YORK --(BUSINESS WIRE)--Mar. 5, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), today announced that management will present at two investor conferences in March: Cowen and Company 39 th Annual Health Care Conference Tuesday, March 12 th 11:20AM Eastern Time Boston, MA Oppenheimer 29 th Annual
On Track to Complete UGN-101 Rolling NDA Submission to the FDA in 2H 2019 Acceleration of Pre-Commercial Activities and Infrastructure Buildout Underway to Support the Potential U.S. Approval and Launch of UGN-101 in 1H 2020 Initial Data from UGN-102 Trial Anticipated in 2019 Conference Call and
Conference Call and Webcast Scheduled for 8:30 AM ET NEW YORK --(BUSINESS WIRE)--Feb. 21, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN) today announced that it will report fourth quarter and full year 2018 financial results on Thursday, February 28, 2019 , prior to the open of the market.
NEW YORK --(BUSINESS WIRE)--Jan. 28, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced the closing of its previously announced public offering of
NEW YORK --(BUSINESS WIRE)--Jan. 22, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology, today announced that it intends to offer and sell $150 million of its ordinary
Data Demonstrates Complete Response (CR) Rate of 57 Percent in Patients with LG UTUC All Evaluated Patients in CR Remain Disease Free at Six Months Rolling Submission of New Drug Application (NDA) Initiated in December 2018 NEW YORK --(BUSINESS WIRE)--Jan. 8, 2019-- UroGen Pharma Ltd.
Ms. Barrett Most Recently Served as CEO for Novartis Oncology and Brings a Track Record of Success in Commercial Oncology NEW YORK --(BUSINESS WIRE)--Jan. 3, 2019-- UroGen Pharma Ltd. (Nasdaq:URGN), a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field
UGN-101 Has the Potential to Become the First Drug Ever Approved for LG UTUC Submission Supported by Pivotal Phase 3 OLYMPUS Study; Topline Results to be Presented in January 2019 Company Expects to Complete NDA Submission by mid-2019, with Potential Approval in 2019 NEW YORK --(BUSINESS
